2. GET
†
5 BONUS SONGS,
FROM OVER 3 MILLION.
Inside Specially Marked 24-Can Packs.
ETET
††
O S SO GOBONUS SONGONUS SONG5 BBO
†Must be legal drinking age. Offer expires on October 31, 2012. Each unique PIN code can be redeemed online for 5 bonus music downloads at kingclub.ca/music. All downloads are for
promotional use only, not for resale, no cash value. Valid in Canada only. Subject to provider’s terms & conditions. Full details available at kingclub.ca. ®/MD Anheuser-Busch, Inc.
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
GET
†
5 BONUS SONGS,
FROM OVER 3 MILLION.
Inside Specially Marked 24-Can Packs.
†Must be legal drinking age. Offer expires on October 31, 2012. Each unique PIN code can be redeemed
online for 5 bonus music downloads at kingclub.ca/music. All downloads are for promotional use only,
not for resale, no cash value. Valid in Canada only. Subject to provider’s terms & conditions. Full details
available at kingclub.ca. ®/MD Anheuser-Busch, Inc.
†Must be legal drinking age. Offer expires on October 31, 2012. Each unique PIN code can be redeemed online for 5 bonus music downloads at kingclub.ca/music.
All downloads are for promotional use only, not for resale, no cash value. Valid in Canada only. Subject to provider’s terms & conditions. Full details available at kingclub.ca. ®/MD Anheuser-Busch, Inc.
GET
†
5 BONUS SONGS,
FROM OVER 3 MILLION.
Inside Specially Marked 24-Can Packs.
A
NEW NIGHT
IS HERE.
®/MD Anheuser-Busch, Inc.
A
HTGNI T
HIS
WNE
EREH
HTGNI
E.
T
A
NEW
NIGHT
ISHERE.
®/MD Anheuser-Busch, Inc.
®/MDAnheuser-Busch,Inc.
EREEH IS
THG
WE
ERE
IGN
NE
EH IS
A
WE
A
NE
A
®/MD Anheuser-Busch, Inc.
NEWNIGHT
IS HERE.
AAAA
NNEEWEWWNNNIGIGGHHTHTNNEEWEWWNNNIGIGGHHTHTNNEEWEWWNNNIGIGGHHTHT
I
N
S
NE
S
E
S
WE
H
W
H
W
H
N
E
N
E
NI
E
GI
R
G
R
GH
R
H
E
TH
E
T
ISSS HHHEEERRREEISSS HHHEEERRREEISSS HHHEEERRREEISSS HHHEEERRREE..
Labatt Brands at Grip Limited
3. THE BRAND
1
1
1
PROGRAM OVERVIEW
HOW IT WORKS
PATIO DOMINATION
ARE YOU IN?
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
†Must be legal drinking age. Limited time offer.
W
GET†A
BUD LIGHT LIME
T-SHIRT
WITH THE PURCHASE OF A
BUD LIGHT & BUD LIGHT LIME
12-CAN MIXER PACK.
*TM/MC Anheuser-Busch, Inc.
A SUBTLE TWIST
OF LIME AND MINT.
Labatt Brands at Grip Limited
6. work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
1 1
The all-new 2012 CR-V is almost here.
The 2012 is coming.
75512A028E
Model shown with accessories.
The a -nall ew 220122 CR V is-R s almmosst he e.er
028E5512A7
“…unparalleled breadth of talent and goodness.”
For the 26th
time in 30 years,the safety, quality and reliability of Honda’s Accord has made it one of Car and Driver’s10Best.
-CarandDriver,January2012
honda.ca
2011
2006
2001
1994
1987
20102009
2004
1999
1990
1985
2005
2000
1991
1986
2008
2003
1998
1989
1984
2007
2002
1995
1988
1983
2012
4:45 PM
Honda at Grip Limited
8. 1312
2.68
warfarin Pradax 150 mg BID
1.38
Efficacy
Demonstrated significantly superior efficacy in BOTH
ischemic and hemorrhagic stroke vs. warfarin, in the
RE-LY trial with >18,000 AF patients1
*A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients received dabigatran
110 mg BID or 150 mg BID (blinded arms) or adjusted doses of warfarin (unblinded arm).
Efficacy: Pr
PRADAX®
150 mg BID vs. warfarin
Bleeding is the most relevant side effect of PRADAX; bleeding of any type or severity occurred in long-term treatment in
16.5% of patients with atrial fibrillation treated for the prevention of stroke and systemic embolism. As with all
anticoagulants, PRADAX should be used with caution in circumstances associated with an increased risk of bleeding.
Bleeding can occur at any site during therapy with PRADAX. Patients at high risk of bleeding should not be prescribed
PRADAX. Close clinical surveillance (looking for signs of bleeding or anemia) is recommended throughout the treatment
period, especially if risk factors are combined. Should severe bleeding occur, treatment with PRADAX must be
discontinued and the source of bleeding investigated promptly. Patients who develop acute renal failure must
discontinue PRADAX.Renal function test should be performed before initiation of therapy and when suspected that the renal
function could decline, to exclude patients with severe renal impairment. The measurement of dabigatran-related
anticoagulation may be helpful to avoid excessive high exposure to dabigatran in the presence of additional risk factors.1
Safety profile
Pradax demonstrated lower risk of intracranial bleeding†
in AF vs warfarin1*§
Annual Rate of Intracranial Bleeding (%)
*Adapted from Pradax Product Monograph.A randomized non-inferiority trial of 18,113 AF patients at risk of stroke.
Patients received dabigatran 110 mg BID or 150 mg BID (blinded arm) or adjusted doses of warfarin (unblinded arm).
§Intracranial bleeding: dabigatran 150 mg BID (n=6076, no. of events=38) vs. warfarin (n=6022, no. of events=90).
†Intracranial bleeding includes adjudicated hemorrhagic stroke, subarachnoid, and/or subdural bleeding.
0.8
0.3
p<0.0001
Stroke or Systemic Embolism1
*
No. of Events Annual Rate (%)
Warfarin
n=6022
202 1.7
Pradax
n=6076
134 1.1
35%
p=0.0001
Ischemic Stroke1
*
No. of Events Annual Rate (%)
Warfarin
n=6022
134 1.1
Pradax
n=6076
103 0.9
25%
p=0.03
Hemorrhagic Stroke1
*
No. of Events Annual Rate (%)
Warfarin
n=6022
45 0.4
Pradax
n=6076
12 0.1
74%
p<0.001
Approximately
80% of all strokes
are ischemic5
12-13 0 2:11 PM
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
PRADAX (dabigatran etexilate) est indiqué pour la prévention de l’AVC et de l’embolie systémique chez les patients atteints de fibrillation auriculaire pouvant
recevoir une anticoagulothérapie.
PRADAX est contre-indiqué chez les patients atteints de ce qui suit : insuffisance rénale grave (ClCr < 30 mL/min); manifestations hémorragiques, diathèse
hémorragique ou patients présentant une altération spontanée ou pharmacologique de l’hémostase; lésions associées à un risque de saignement significatif
sur le plan clinique, telles qu’un infarctus cérébral étendu (hémorragique ou ischémique) au cours des 6 derniers mois, ulcère gastrique en évolution avec
saignement récent; traitement concomitant par inhibiteurs puissants de la P-glycoprotéine tels que le kétoconazole administré par voie orale et hypersensibilité
connue au dabigatran, au dabigatran etexilate ou à tout autre ingrédient contenu dans la préparation du produit ou composant du contenant.
Le saignement est l’effet secondaire le plus important de PRADAX; un saignement de toute nature ou gravité a été observé chez 16,5 % des patients souffrant
de fibrillation auriculaire ayant reçu un traitement de longue durée visant à prévenir l’AVC et l’embolie systémique. Comme c’est le cas avec tous les
anticoagulants, PRADAX devrait être utilisé avec précaution lorsqu’il existe un risque plus élevé de saignement. Un saignement peut survenir n’importe où dans
l’organisme durant le traitement par PRADAX. PRADAX ne devrait pas être prescrit aux patients à risque élevé de saignement. Une surveillance clinique étroite
(visant à détecter tout signe de saignement ou d’anémie) est recommandée durant la période de traitement, surtout en présence de facteurs de risque. En cas
de saignement grave, le traitement par PRADAX doit être interrompu et la source du saignement rapidement recherchée. Les patients qui présentent
une insuffisance rénale aiguë pendant le traitement par PRADAX devraient cesser de prendre ce médicament. La fonction rénale devrait être évaluée avant
l’instauration du traitement et si l’on soupçonne que la fonction rénale pourrait se détériorer afin d’exclure les patients atteints d’insuffisance rénale grave.
L’innocuité et l’efficacité de PRADAX n’ont pas été évaluées chez des patients présentant des valvules cardiaques mécaniques ou ceux atteints de rhumatisme
cardiaque significatif sur le plan hémodynamique, dont une sténose mitrale. Par conséquent, l’administration de PRADAX n’est pas recommandée.
Les agents pouvant augmenter le risque d’hémorragie ne devraient pas être administrés en association avec PRADAX ou, si nécessaires, devraient être
administrés avec précaution durant le traitement par PRADAX. L’administration concomitante de dronédarone augmente l’exposition à PRADAX et n’est pas
recommandée. Le risque de saignement pourrait être plus élevé chez les patients qui reçoivent un traitement concomitant par inhibiteur sélectif du recaptage de
la sérotonine (ISRS). Chez les patients souffrant de fibrillation auriculaire et recevant un traitement visant à prévenir l’AVCet l’embolie systémique, l’administration
concomitante d’antiplaquettaires par voie orale (comme l’AAS et le clopidogrel) et d’AINS augmente le risque de saignement d’environ deux fois. L’administration
concomitante de PRADAX et de l’inducteur puissant de la P-gp rifampicine diminue les concentrations plasmatiques de dabigatran et, par conséquent, devrait
être évitée. Veuillez consulter la monographie du produit pour obtenir des renseignements additionnels sur les traitements qui augmentent le risque d’hémorragie.
Prière de consulter la monographie du produit pour l’information sur l’ajustement posologique chez certaines populations particulières.
Les manifestations indésirables les plus courantes observées chez 1 % des patients ayant reçu PRADAX à 150 mg bid et à 110 mg bid comprenaient : anémie
(1,6 %, 1,2 %), épistaxis (1,1 %, 1,1 %), hémorragie gastro-intestinale (4,6 %, 3,3 %), hémorragie uro-génitale (1,4 %, 1,1 %), douleur abdominale (2,2 %,
2,3 %), diarrhée (1,2 %, 1,3 %), dyspepsie (3,9 %, 4,2 %) et nausée (1,2 %, 1,0 %), respectivement. Des réactions indésirables gastro-intestinales sont
survenues plus fréquemment avec le dabigatran etexilate qu’avec la warfarine, et avaient trait à la dyspepsie (incluant douleur abdominale supérieure, douleur
abdominale, malaise abdominal, malaise épigastrique) ou à des symptômes de pseudo-gastrite (incluant reflux gastro-œsophagien, œsophagite, gastrite
érosive, hémorragie gastrique, gastrite hémorragique, gastrite érosive hémorragique et ulcère gastro-intestinal). Une hémorragie gastro-intestinale est survenue
plus fréquemment avec le traitement par PRADAX à 150 mg bid et à 110 mg bid (4,6 % et 3,3 %, respectivement) comparativement au traitement par warfarine
(2,6 %). Le mécanisme sous-jacent expliquant le taux plus élevé d’hémorragies gastro-intestinales avec PRADAX n’a pas été établi.
Des réactions allergiques ou une hypersensibilité médicamenteuse, y compris l’urticaire, un bronchospasme, une éruption cutanée et un prurit, ont été
rapportées par des patients ayant reçu du dabigatran etexilate. De rares cas de réactions anaphylactiques ont également été rapportés.
Pour obtenir le guide thérapeutique complet, prière de consulter la monographie du produit.
Chez les patients atteints
de fibrillation auriculaire,
Pradax a démontré :
Comme c’est le cas avec tous les anticoagulants, PRADAX devrait être utilisé avec précaution lorsqu’il existe
un risque plus élevé de saignement. Un saignement peut survenir n’importe où dans l’organisme durant
le traitement par PRADAX. En cas de saignement grave, le traitement par PRADAX doit être interrompu
et la source du saignement rapidement recherchée.
Les patients présentant un risque plus élevé de saignement devraient faire l’objet de surveillance clinique étroite.
Un test de la coagulation, tel que le test du temps de céphaline activée peut être utile pour identifier les patients
qui présentent un risque plus élevé de saignement dû à une exposition excessive au dabigatran.
*Étude de non-infériorité à répartition aléatoire menée auprès de 18 113 patients atteints de FA prédisposés à l’AVC.
Les patients recevaient soit le dabigatran à 110 mg bid ou à 150 mg bid (groupe à l’insu) ou des doses ajustées de warfarine (groupe ouvert).
†AVC ou embolie systémique : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 134) par rapport à la warfarine (n = 6 022, nombre d’événements = 202).
¥AVC ischémique : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 103) par rapport à la warfarine (n = 6 022, nombre d’événements = 134).
‡L’hémorragie intracrânienne comprend les AVC hémorragiques attestés et les hémorragies sous-arachnoïdiennes et/ou sous-durales.
§Hémorragie intracrânienne : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 38) par rapport à la warfarine (n = 6 022, nombre d’événements = 90).
¢L’hémorragie menaçant la vie était une sous-catégorie de l’hémorragie majeure et incluait : hémorragie mortelle, hémorragie intracrânienne symptomatique, hémorragie avec
baisse du taux d’hémoglobine d’au moins 50 g par litre ou hémorragie nécessitant la transfusion d’au moins 4 unités de sang ou d’agents inotropes ou nécessitant une chirurgie.
£Hémorragie majeure menaçant la vie : dabigatran à 150 mg bid (n = 6 076, nombre d’événements = 179) par rapport à la warfarine (n = 6 022, nombre d’événements = 218).
BIPRA111328F
Visitez Pradax.ca
Pr
PRADAX®
à 150 mg bid
Indiqué pour la prévention de l’accident vasculaire cérébral (AVC)
et de l’embolie systémique chez les patients atteints de fibrillation auriculaire (FA)
pouvant recevoir une anticoagulothérapie1
.
Est-ce que Pradax à 150 mg bid est une option thérapeutique
pour ces patients atteints de FA?
Patients à risque élevé
Pour toute question au sujet de Pradax, composez le 1-855-PRADAX5 (772-3295).
PATIENTS ATTEINTS DE FAPRADAX À VOS
PRESCRIVEZ
PRÉDISPOSÉS À L’AVC
Réduction du risque d’AVC ou d’embolie
systémique de 35 % par rapport à la warfarine1*†
Dabigatran à 150 mg bid (1,1 %/an) par rapport à la warfarine (1,7 %/an), p=0,0001.
Réduction du risque d’AVC ischémique de 25 %
par rapport à la warfarine1*¥
Dabigatran à 150 mg bid (0,9 %/an) par rapport à la warfarine (1,1 %/an), p=0,03.
Risque d’hémorragie intracrânienne‡
moins élevé
de 59 % par rapport à la warfarine1*§
Dabigatran à 150 mg bid (0,3 %/an) par rapport à la warfarine (0,8 %/an), p<0,0001.
Risque d’hémorragie menaçant la vie¢
moins élevé
de 20 % par rapport à la warfarine1*£
Dabigatran à 150 mg bid (1,5 %/an) par rapport à la warfarine (1,9 %/an), p=0,0305.
Aucune surveillance du RIN1
Références : 1. Monographie de Pradax. Boehringer Ingelheim (Canada) Ltée, 27 janvier 2012. 2. Skanes Allan C et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation
Guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-136.
Pradax®
est une marque déposée utilisée sous licence par Boehringer Ingelheim (Canada) Ltée.
B 1-3 2 11:51 AM
WITH PRADAXPREVENT STROKE
HELP
AND SYSTEMIC EMBOLISM
See prescribing summary on page
Pr
PRADAX®
150 mg BID INDICATED FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN
PATIENTS WITH ATRIAL FIBRILLATION, IN WHOM ANTICOAGULATION IS APPROPRIATE.1
Pr
PRADAX®
carbamazepine are also expected to reduce dabigatran plasma concentrations
and should be co-administered with caution.
The most common adverse reactions observed in 1% of PRADAX 150 mg
BID patients and 110 mg BID patients was anemia (1.6%, 1.2%), epistaxis
(1.1%, 1.1%), gastrointestinal hemorrhage (4.6%, 3.3%), urogenital
hemorrhage (1.4%, 1.1%), abdominal pain (2.2%, 2.3%), diarrhea (1.2%,
1.3%), dyspepsia (3.9%, 4.2%) and nausea (1.2%, 1.0%), respectively.
Gastrointestinal adverse reactions occurred more often with dabigatran
etexilate than warfarin. These were related to dyspepsia (including upper
abdominal pain, abdominal pain, abdominal discomfort, epigastric discomfort)
or gastritis-like symptoms (including GERD, esophagitis, erosive gastritis,
gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis and
gastrointestinal ulcer). Gastrointestinal hemorrhage occurred at a higher
frequency with PRADAX 150 mg BID and 110 mg BID (4.6%, 3.3%,
respectively) compared to warfarin (2.6%). The underlying mechanism of the
increased rate of GI bleeding has not been established.
Allergic reactions or drug hypersensitivity including urticaria, bronchospasm,
rash and pruritus have been reported in patients who received dabigatran
etexilate. Rare cases of anaphylactic reactions have also been reported.
Patients at an increased risk of bleeding should be closely monitored clinically.
A coagulation test, such as aPTT may help to identify patients with an
increased bleeding risk caused by excessive dabigatran exposure.
For complete prescribing information, please refer to the Product Monograph.
*A randomized non-inferiority trial of 18,113 AF patients at risk of stroke. Patients
received dabigatran 110 mg BID or 150 mg BID (blinded arm) or adjusted doses of
warfarin (unblinded arm).
†Stroke or systemic embolism: dabigatran 150 mg BID (n=6076, no. of events=134)
vs. warfarin (n=6022, no. of events=202).
‡Intracranial bleeding includes adjudicated hemorrhagic stroke, subarachnoid,
and/or subdural bleeding.
§Intracranial bleeding: dabigatran 150 mg BID (no. of events=38) vs. warfarin
(no. of events=90).
References: 1. Pradax Product Monograph. Boehringer Ingelheim (Canada) Ltd., 06/13/11.
2. Connolly SJ et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med.
2009;361:1139–1151. 3. Connolly SJ et al. Newly Identified Events in the RE-LY Trial. N Engl J Med.
2010;363:1875-1876 supp appendix. 4. Liste de médicaments publiée par la Régie de l’assurance
maladie du Québec. April 2011.
Pradax®
is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.
PRADAX (dabigatran etexilate) is indicated for the prevention of stroke and
systemic embolism in patients with atrial fibrillation, in whom anticoagulation
is appropriate.
PRADAX is contraindicated in patients with: severe renal impairment
(CrCL <30 mL/min); hemorrhagic manifestations, bleeding diathesis, or
patients with spontaneous or pharmacological impairment of hemostasis;
lesions at risk of clinically significant bleeding, e.g. extensive cerebral
infarction (hemorrhagic or ischemic) within the last 6 months, active peptic
ulcer disease with recent bleeding; concomitant treatment with strong
P-glycoprotein (P-gp) inhibitors, i.e. oral ketoconazole, and with known
hypersensitivity to dabigatran, dabigatran etexilate or to any ingredient in the
formulation or component of the container.
Bleeding is the most relevant side effect of PRADAX; bleeding of any type or
severity occurred in long-term treatment in 16.5% of patients with atrial
fibrillation treated for the prevention of stroke and systemic embolism. As with
all anticoagulants, PRADAX should be used with caution in circumstances
associated with an increased risk of bleeding. Bleeding can occur at any site
during therapy with PRADAX. An unexplained fall in hemoglobin and/or
hematocrit or blood pressure should lead to a search for a bleeding site.
Patients at high risk of bleeding should not be prescribed PRADAX. Close
clinical surveillance (looking for signs of bleeding or anemia) is recommended
throughout the treatment period, especially if risk factors are combined.
Should severe bleeding occur, treatment with PRADAX must be
discontinued and the source of bleeding investigated promptly. Patients
who develop acute renal failure must discontinue PRADAX. In patients who
are bleeding, an aPTT test may be useful to assist in determining an excess
of anticoagulant activity, despite its limited sensitivity. An aPTT >80 sec at
trough, i.e. when the next dose is due, is associated with a higher risk of
bleeding.
Agents that may enhance the risk of hemorrhage should not be administered
concomitantly with PRADAX, or, if necessary, should only be administered
with caution. Treatments that should NOT be administered concomitantly
with PRADAX due to increase in bleeding risk include: unfractionated
heparin and heparin derivatives, low molecular weight heparins
(LMWH), fondaparinux, bivalirudin, thrombolytic agents, GPIIb/IIIa
receptor antagonists, ticlopidine, sulfinpyrazone and vitamin K
antagonists such as warfarin. The concomitant use of PRADAX with the
following treatments has not been studied and may increase the risk of
bleeding: rivaroxaban, prasugrel and the strong P-gp inhibitors
dronedarone, itraconazole, tacrolimus, cyclosporine, ritonavir,
tipranavir, nelfinavir and saquinavir. Unfractionated heparin may be
administered at doses necessary to maintain a patent central venous or
arterial catheter. In patients with atrial fibrillation treated for the prevention of
stroke and systemic embolism, the co-administration of oral anti-platelet
(including ASA and clopidogrel) and NSAID therapies increases the risk of
bleeding by about two-fold. If necessary, co-administration of low-dose ASA,
i.e. 100 mg daily with PRADAX may be considered for other indications than
stroke prevention in atrial fibrillation. The concomitant use of PRADAX with
the strong P-gp inducer, rifampicin, reduces dabigatran plasma
concentrations. Other P-gp inducers such as St. John’s Wort or
For patients with atrial fibrillation, PRADAX demonstrated:
reduced risk of stroke or
systemic embolism vs. warfarin1-3*†
Dabigatran 150 mg BID (1.1%/yr)
vs. warfarin (1.7%/yr), p=0.0001.
reduced risk of intracranial
bleeding‡
vs. warfarin1-3*§
Dabigatran 150 mg BID (0.3%/yr)
vs. warfarin (0.8%/yr), p<0.0001.
No INR monitoring or dose titration1
Covered by the
Liste de
médicaments
du Québec
with Exception
Drug Status4
12:56 PM
Pr
Pradax®
for
Stroke and Systemic
Embolism Prevention
in Atrial Fibrillation
A guide to support the use of Pradax.
1 0 2:10 PM
AVOID BRAND NAME
CONFUSIONBETWEEN
Pr
PRADAX®
AND
Pr
PLAVIX®
The Pradax®
and Plavix®
names, verbally and by script, have been mistaken for one another.
These mix-ups have been associated with similarities in orthographics, phonetics and strength.
To reduce the potential for name confusion errors, healthcare professionals are encouraged
to include the generic name dabigatran when referring to Pradax®
, or the name clopidogrel
when referring to Plavix®
. Spelling the name of the medication for verbal prescriptions
is also suggested.
Pradax®
is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.
Plavix®
is a registered trademark used under license by Sanofi-aventis Canada Inc.
BIPRA121200E
Pradax at Grip Limited
10. Veracity Capital Inc.
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
Integrated
Facility
Solutions, Inc.
yyyy
yyyyyyyyy
yyyy
yR E G I O N A L M E D I C A L R E S E A R C H
RECHERCHE MÉDICALE RÉGIONALE
furniture designarchitecture
professional services
healthcare
financial
technology
leisure
fashion
Pavel is responsible for designing and implementing over 40 logos
for corporate, manufacturing, pharmaceutical, retail and fashion clients.
The following pages showcase select work samples ranging from
logo design and corporate brochures to marketing and advertising campaigns.
11. work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
Which would you rather have, a cholesterol test
or a final exam?
For many, the first sign of heart disease is a heart
attack. Did you know that one out of two adult
Canadians is at risk of developing heart
disease because they have high cholesterol?
And that cardiovascular disease IS the
leading cause of death in Canada?
High cholesterol is a major risk factor
for heart disease but managing your
cholesterol can be quite simple.
If any of these apply to you,
cut this screening test out and ask
your doctor about getting your
cholesterol tested:
Woman 50 years or older
Man 40 years or older
Heart disease (angina, heart
attack, coronary bypass, stroke,
angioplasty)
Diabetes
Family history (mother, father,
sister, brother or grandparent) of
heart disease or high cholesterol
Two or more of the following:
• Overweight
• Physically inactive
• Smoker
• High blood pressure
Call toll-free at
1-877-4-LOW-LDL
(1-877-456-9535) or visit
www.makingtheconnection.ca
and you will receive this
free booklet describing the
connection between cholesterol
and heart disease.
The Canadian Diabetes Association has reviewed the “Making the Connection” program for its medical and scientific
accuracy. The Canadian Diabetes Association does not endorse the products of any pharmaceutical company.
Sponsored by one of Canada’s research based pharmaceutical companies.
Use your Shopping Companion to
chart your low-cholesterolfood
choices and recipe ingredients.
Keep this journal handy
for when you go groceryshopping.
Managing your
cholesterol
pharmaceutical
12. atorvastatine calcique
comprimés
EFFICACE POUR VISER JUSTE
Efficacité…
Expérience…
Études à l’appui, dans
l’atteinte de la cible de
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
YOUR ANTIHYPERTENSIVE THERAPY SHOU LD BE AS DEPENDABLE AS THE SUNRISE
Prolonged & Sustained 24-Hour Blood Pressure Control
L Provided similar efficacy in clinic [trough] blood pressure reduction to Norvasc* (amlodipine)1‡
L “…was also associated with a greater reduction in ambulatory blood pressure during the night-
time interval and during the last 4 hours of the dosing period”than Norvasc* (amlodipine)1
L MICARDIS® (40-80 mg) demonstrated at least similar efficacy to Vasotec®
(5-20 mg)2,3ƒ
L Significantly more effective than Cozaar®
50 mg (losartan) in blood pressure reduction
18-24 hours post-dose4%
Excellent Pharmacokinetic Profile
L 24-hour half-life,longest of all AT1 receptor blockers3†§
L Fastest time to maximum plasma concentration3†§
L Trough to peak ratio 92-100% for 80 mg5,6
L 97% hepatic excretion3
Excellent Tolerability#
L Discontinuation rate due to adverse events was less with
MICARDIS® (2.8%) than with placebo (6.1%)3#
L Excellent drug interaction profile3#
L Not metabolized by cytochrome P450 isoenzymes3
Simple Dosing
L 80 mg once-a-day starting and maintenance dose,
regardless of age,gender or renal status3
L No titration required3
L Can be taken with or without food3
FULL 24-HOUR PROTECTION,INCLUDING
THE CRITICAL EARLY MORNING HOURS
HYPERTENSION NEVER TAKES TIME OFF...
NEITHER SHOULD YOUR
ANTIHYPERTENSIVE
NEW
T E L M I S A R TA N 8 0 m g AT1 R E C E P T O R B L O C K E R
®
Pr
Antihypertensive protection day and night.
NEW
T E L M I S A R TA N 8 0 m g AT1 R E C E P T O R B L O C K E R
Pr
®
Co-promoted with
*TM Pfizer Products Inc., Pfizer Canada Inc., licensee. ® Trademark Merck & Co., Inc./Merck Frosst Canada Inc., licensed user. Cozaar®
is a registered trademark of E.I. du Pont de Nemours and Company, Merck Frosst & Co., licensed user.
References: 1. Lacourcière Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Pressure Monitoring 1998;3(5):295-302. 2. Smith DHG, Neutel JM, Morgenstern P.
Once-Daily Telmisartan Compared with Enalapril in the Treatment of Hypertension. Advances in Therapy 1998;16(4):229-240. 3. MICARDIS® Product Monograph, Boehringer Ingelheim (Canada) Ltd. August, 1999. 4. Mallion JM, Lacourcière Y.
ABPM Comparison of the Antihypertensive Profiles of the Selective Angiotensin II Receptor Antagonists Telmisartan and Losartan in Patients with Mild-to-Moderate Hypertension. The Journal of Human Hypertension (In press). 5. Bakris G, et al.
Clinical Efficacy and Safety Profiles of AT1 Receptor Antagonists. CVR&R 1999; February 1999:78-100. 6. Neutel JM, Smith DHG. Dose Response and Antihypertensive Efficacy of the AT1 Receptor Antagonist Telmisartan in Patients with Mild to
Moderate Hypertension. Advances in Therapy 1998;15(4):206-217.
MICARDIS® (telmisartan) is indicated for the treatment of mild to moderate hypertension.
MICARDIS® may be used alone or in combination with thiazide diuretics.
MICARDIS® should normally be used in those patients in whom treatment with diuretic or beta blocker was found ineffective or has been associated with unacceptable adverse effects.
MICARDIS® can also be tried as an initial agent in those patients in whom the use of diuretics and/or beta blockers is contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects.
If pregnancy is detected, MICARDIS® should be discontinued as soon as possible.
In patients who are volume-depleted by diuretic therapy, dietary salt restrictions, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDIS®.
‡ Results from 12-week double-blind phase, 40 mg MICARDIS® (n=73) and 5 mg Norvasc* (n=78), p<0.0001
Similar reduction in DBP was observed over the 24-hour mean period. Results after 12 weeks monotherapy as
measured by 24-hour ABPM with MICARDIS® (n=73; increased to 80 and 120 mg as necessary for patients
whose DBP remained >90 mmHg) and Norvasc* (n=78; titrated to 5 mg and titrated to 10 mg for patients whose
DBP remained >90 mmHg). p<0.05. The recommended dose of MICARDIS® is 80 mg once-daily, 120 mg provided
no additional mean reduction in blood pressure.
ƒ There was similar reduction in DBP at weeks 1, 4 , and 8. MICARDIS® 80 mg (n=72), Vasotec®
20 mg (n=72),
p=0.03 for DBP, p=0.01 for SBP.
% ABPM 18-24h post-dose period comparing Cozaar®
50 mg (n=50) and MICARDIS® 40 and 80 mg (n=52) at week
6 of therapy p<0.05.
† From product monographs of valsartan, losartan, irbesartan, and candesartan.
#The most common adverse events are headache, upper respiratory tract infection and dizziness.
§ Comparative clinical significance is investigational.
# Digoxin levels should be monitored when initiating, adjusting, or discontinuing MICARDIS®.
No initial dosing adjustment is necessary for elderly patients or for patients with renal impairment, but greater
sensitivity in some older individuals cannot be ruled out. For patients with hepatic impairment, a starting dose of
40 mg is recommended.
LIPITOR*
: Hitting targets.
LIPITOR is an HMG-CoA reductase inhibitor (statin). LIPITOR is indicated as an adjunct to lifestyle changes, including diet, for the reduction of elevated total cholesterol, LDL-C, TG and
apolipoprotein B in hyperlipidemic and dyslipidemic conditions (including primary hypercholesterolemia, combined [mixed] hyperlipidemia, dysbetalipoproteinemia, hypertriglyceridemia
andfamilialhypercholesterolemia)whenresponsetodietandothernon-pharmacologicalmeasuresalonehasbeeninadequate.
LIPITOR also raises HDL-cholesterol and therefore lowers the LDL-C/HDL-C and Total-C/HDL-C ratios (Fredrickson Type IIa and IIb). These changes in HDL-C with HMG-CoA reductase
inhibitorsshouldbeconsideredasmodestwhencomparedtothoseobservedinLDL-CanddonotplayaprimaryroleintheloweringofLDL-C/HDL-CandTotal-C/HDL-Cratios.
Seeprescribinginformationforcompletewarnings,precautions,dosingandadministration.
LIPITORiscontraindicated:Duringpregnancyandlactation;activeliverdiseaseorunexplainedpersistentelevationsofserumtransaminasesexceeding3timestheupperlimitofnormal;
hypersensitivitytoanycomponentofthismedication.
Lipidlevelsshouldbemonitoredperiodicallyand,ifnecessary,thedoseofLIPITORadjustedbasedontargetlipidlevelsrecommendedbyguidelines.
Cautionshouldbeexercisedinseverelyhypercholesterolemicpatientswhoarealsorenallyimpaired,elderly,orareconcomitantlybeingadministereddigoxinorCYP3A4inhibitors.
Liverfunctiontestsshouldbeperformedbeforetheinitiationoftreatment,andperiodicallythereafter.Specialattentionshouldbepaidtopatientswhodevelopelevatedserumtransaminase
levels,andinthesepatientsmeasurementsshouldberepeatedpromptlyandthenperformedmorefrequently.
Theeffectsofatorvastatin-inducedchangesinlipoproteinlevels,includingreductionofserumcholesteroloncardiovascularmorbidity,mortality,ortotalmortalityhavenotbeenestablished.
‡Apatient-yearrepresentsthetotaltimeofexposuretoLIPITORasdefinedbythesumofeachpatienttimeonLIPITOR.5
¥TheAtorvastatinVersusRevascularizationTreatments(AVERT)studyexaminedtheeffectofintensivelipid-loweringinpatientswithstablecoronaryarterydiseaseandLDL-Catleast3.0
mmol/Linpatientsreferredforpercutaneoustransluminalcoronaryangioplasty(PTCA).Patientswererandomizedfor18monthstoLIPITOR80mgdailyortoPTCAwithusualmedical
carewhichcouldincludelipidmetabolismregulators.TheresultsoftheAVERTstudyshouldbeconsideredasexploratorysinceseverallimitationsmayaffectitsdesignandconduct.In
themedical-treatedgroupwithLIPITORtherewasatrendforareducedincidenceofischemiceventsandadelayedtimetofirstischemicevent.Theresultsalsosuggestthatintensive
treatmenttotargetLDL-ClevelswithLIPITORisadditiveandcomplementarytoangioplastyandwouldbenefitpatientsreferredforthisprocedure.1
39-60%1†
LDL-C TG
25-56%
(type IV)1†
29-44%
TC/HDL-C
(type IIa and IIb)1†
Clinical
research
program4
EFFICACY ¢ † A powerful demonstrated effect across
key lipid parameters1
EXPERIENCE ¢ More than 40 million patient-years of experience2‡
EVIDENCE ¢ Demonstrated delayed time to first ischemic
event in stable CAD patients (n=164, p=0.03)3¥
LIPITOR has a leading edge clinical research program exploring
new areas that may extend beyond lipid control4
Aiming
beyond.
Aiming
beyond.
pharmaceutical
Because the
early morning
hours are critical...
Full 24-Hour Protection
from BP Surges,
Including the Critical
Early Morning Hours
Because the
early morning
hours are critical...
Full 24-Hour Protection
from BP Surges,
Including the Critical
Early Morning Hours
13. JSAI
Training marketers to be marketects
JEFFREY SIMBROW ASSOCIATES INC.
JSAI
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
JSAI Introduction
Jeffrey Simbrow Associates Inc. (JSAI) offers a curriculum of interactive skill-based
seminars designed to enhance the competencies of marketing executives to become more
effective brand builders. Our training seminars, utilizing best practices, are provided in
marketing and brand planning, positioning and communication strategy development,
advertising development, research, promotion and media planning.
JSAI’s internationally acclaimed training seminars have been executed for companies around
the world for industries as diverse as brewing, pharmaceutical, financial services,
entertainment, professional sports, food and packaged goods. Our clients include leading
companies such as Interbrew, Pepsi Quaker
Tropicana Gatorade Canada, Pfizer, Schering, Eli
Lilly, Corus Entertainment, Alliance Atlantis, Toronto
Blue Jays, Toronto Dominion Bank… To date, we
have conducted more than 100 programs throughout
the world including Toronto, Montreal, New York,
San Francisco, Los Angeles, London, Tokyo, Seoul,
Brussels, Budapest, Amman, Singapore, Bangkok,
Rome, Paris, Helsinki and other major cities. We
have trained more than 2,500 marketing managers
worldwide to become “marketects”.
Who Should Attend
JSAI training seminars provide an unparalleled idea-sharing and network opportunity for
a select group of senior managers. Typical titles include Chief Marketing Officer, Vice
President Marketing, Marketing Director, Sales Director, Brand Manager, Assistant Brand
Manager, Sales Manager, Marketing Research Manager, Advertising Agency Consultant, etc.
3
JSAI Introduction 3
Overall Objectives 4
JSAI Strengths 5
Training Programs 6
Speaker Bio 14
Case Studies 15
Client Testimonials 16
Contact Information 18
2
13
Media Planning [Code 006]
Objectives:
To become familiar with/understand the language of media
To understand the basic principles underlying the construction of a media plan in
order to:
• Challenge/suggest alternatives to agency media recommendations
• Defend/explain media choices
Contents:
Key Media Terms
Strength and Weakness of Media Classes
The Media Planning Process
• Information Required
• Media Objectives
• Media Strategies
• Media Tactics
• Media Tools – Research
• What the Media Plan Should Look Like
– Plan Evaluation Checklist
Plan Execution
• Market Dynamics Media Classes
12 JSAI
marketing training
14. work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
Prepared by Jeffrey Simbrow Associates Inc.
USA June 2002
Interbrew
Promotion
Training
Program
Prepared by Jeffrey Simbrow Associates Inc.
Prepared by Jeffrey Simbrow Associates Inc.
M A R K E T I N G T R A I N I N G P R O G R A MM A R K E T I N G T R A I N I N G P R O G R A M
Prepared by Jeffrey Simbrow Associates Inc.
Prepared by Jeffrey Simbrow Associates Inc.
Prepared by Jeffrey Simbrow Associates Inc.
marketing training
15. work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
All About
The Sharp
LCD TV Guide
Top consumer
myths about LCD
technology
Topconsumermyths
aboutLCDtechnology
Wide Viewing Angle
The AQUOS provides
a wide viewing angle
of 170 degrees, both
horizontally and
vertically, allowing you
to view the screen clearly
from virtually anywhere
in a room, regardless of what angle the TV or viewer is positioned in.
Clear Reproduction of Fast Moving Video Clips
Another benefit that Sharp ASV technology brings to LCD is Sharp’s
proprietary Quick Shoot component. Quick Shoot improves the quality of
moving scenes on liquid crystal panels by achieving exceedingly high
response times resulting in unsurpassed picture playback and realism.
High Performance Liquid Crystal Control
Sharp’s High Performance LC control technology is a key benefit of
the AQUOS line-up. The liquid-crystal displays (LCDs) in use today rely
on picture elements, or pixels, formed by liquid-crystal (LC) cells that
change the polarization direction of light passing through them in
response to an electrical voltage.
As the polarization direction changes, more or less of the light is able
to pass through a polarizing layer on the face of the display. Change the
voltage, and the amount of light is changed. Sharp ASV technology has a
high level of control over individual pixels allowing for the reproduction
of thicker and darker contrast enabled blacks.
Best in Class Picture Quality
It’s not enough to build a bigger panel. As the panels become larger
the need for a higher resolution panel becomes even more evident.
For example, the Sharp LC37G4U has a unique High-Definition LCD Panel
which packs over 3.1 million pixels in a 37" display.
Compared to a plasma TV of the same screen size, this LCD panel has
30 per cent more horizontal pixels delivering a highly precise, super-
realistic picture.
All About AQUOS: The Sharp LCD TV Guide
INTRODUCTION TO AQUOS 3
Horizontal
170°
Vertical
170°
Conventional LCD Advanced Super View with Quick Shoot
technology
16. The Canadian Pharmaceutical Marketing Program
Learning to
build stronger
healthcare brands
• Improve profitability
• Gain market advantage
• Maximize value through the
entire product lifecycle
www.humber.ca/healthindustry
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
The Canadian Pharmaceutical Marketing Program
Learning to
build stronger
healthcare brands
4-day Professional
Development Program
Developed for the industry, by the industry, the Canadian
Pharmaceutical Marketing Program is a unique, practical
career development program that approaches marketing
from a healthcare perspective. Over the course of four
intensive full-day sessions, participants will learn best
practices for designing and implementing a successful brand
strategy in today’s dynamic pharmaceutical marketplace.
New product managers, associate product managers, and
others involved in planning and implementing marketing
strategies will walk away with an actionable framework
that can be immediately applied to:
• Improve profitability
• Gain market advantage
• Maximize value through the entire product lifecycle
• Largest 4-year nursing degree program
offered exclusively at a college
• Focus on primary health care & advocacy
• Outstanding faculty with professional practice
& teaching experience
• Exceptional nursing simulation & anatomy labs
• Full and part-time practical nursing diploma
humber.ca/healthsciences • 416.675.5000
Congratulations to the first graduates of
the UNB-Humber Bachelor of Nursing Degree
(June 2005)
• Largest nursing program in Ontario
• Diverse full-time and
part-time programs
• Academic and clinical excellence
• Outstanding faculty and
teaching excellence
• Modern, high-tech facilities
humber.ca/healthsciences
416.675.5000
Diplomas • Certificates • Bachelor’s Degree in Nursing
Postgraduate Programs • Continuing Education
education
17. work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
N
Enclosed Area CoverageEnclosed Area Coverage
CHANEXCOMCHANEXCOM
N owhere are coverage problems more
apparent than in enclosed areas. Anyone
who has tried to use a mobile radio or
cellular phone in buildings, tunnels or
subways knows the feeling.
Futurecom’s CHANEXCOM is a system
solution specifically designed to solve
e n c l o s e d - a r e a c o v e r a g e p r o b l e m s .
I t p r o v i d e s t h e n e c e s s a r y
equipment for off-air signal
acquisition and enclosed area
RF distribution. It assures seam-
less integration of external and
internal coverage areas.
CHANEXCOM Channel Mod-
ules (CMD) ensure that only wanted
channels are allowed into coverage
extension areas, minimizing possi-
ble intermod and interference
problems. Channel Modules are
high specification, channel-selec-
tive repeaters capable of handling
digital and analog signals.
CHANEXCOM Channel Modules
can be programmed to work on-
channel or as frequency translators.
They are typically used to process
signals off-air at a head-end site. Signals can
then be distributed within the extended cov-
erage areas by conventional coaxial cables,
or over longer distances by fiber optics.
Distributed antennas or leaky coax cable
are used to radiate the signals in the
enclosed areas.
LA3B Tri-band Line Amplifiers are used
to compensate for signal losses over long
cable runs. When equipped with an option-
al AGC board they become smart, remotely
controlled devices.
CHANEXCOM supports VHF,
UHF, and 800/900 MHz fre-
q u e n c y b a n d s a n d c a n b e
equipped for remote monitoring and
control operation. This allows all
remote device settings to be opti-
mized from one central location
and provides for alarm and fail-
safe reconfiguration functionality.
CHANEXCOM Digs In
Futurecom’s CHANEXCOM enclosed
area coverage solutions have been
proven in the most demanding envi-
r o n m e n t s , i n c l u d i n g s u b w a y
systems in Toronto, New York City
and Los Angeles, Toronto’s “Under-
ground City” and Major Shopping
Malls and Office Tower Complexes
throughout the world.
CHANEXCOM is recognized among Public
Safety Agencies as the mission critical cov-
erage extension solution.
CHANEXCOM
FIBER OPTIC
BACKBONE
LA3B
CHANEXCOM
FIBER OPTIC
BACKBONE
LA3B
LA3B
LA3B
LA3B
LA3B
LA3B
LA3B
PProviding high-quality portable radio cover-
age in wide-area systems and high-density
urban environments is one of the greatest chal-
lenges facing today’s radio system designers.
Their task becomes even more demanding when
additional factors such as cost, reliability, and
shortage of spectrum become part of the equa-
tion. Life would be much easier for these
hard-pressed system designers if only high qual-
ity portable coverage could be provided from
systems designed for mobile grade coverage.
Futurecom’s MOBEXCOM Vehicular
Repeater System (VRS) is one solution that can
solve some of the system designers’ portable
coverage problems.
M O B E X C O M p r o -
vides portable grade
coverage in systems
designed for mobile
c o v e r a g e . W h e n
mounted in a vehicle
and integrated with the system mobile it
extends system coverage for personnel oper-
ating with portables.
MOBEXCOM can be seen as a Trunking
Gateway between a trunking and a conven-
tional system. The Trunking Gateway operates
like a trunking radio on the system side and
as a conventional radio on the local portable
side. It receives group and private calls and
retransmits them to the portable radio. The
portable radio calls are converted into the
group calls and retransmitted to the system.
The Gateway can be configured for in-band
or cross-band applications. The in-band con-
figuration is particularly beneficial as the same
portable radio can be used for communica-
tions directly with the system or via the VRS.
Local Area CoverageLocal Area Coverage
MOBEXCOMMOBEXCOM
Going from system to local coverage requires
only a change of channel. The Trunking Gate-
way is fully integrated with the trunking radio
and controlled by the mobile control head. It
also supports all important trunking system fea-
tures such as “go ahead” tones, group/private
calls and portable emergency transmissions.
The Trunking Gateway in a mobile appli-
cation provides portable radio coverage in
systems designed for mobile coverage. In a
fixed application it provides a cost effective
in-building coverage extension, requiring only
a single-channel distribution system that is far
less costly to implement than a multi-channel
design. As the Trunk-
ing Gateway operates
on a different fre-
q u e n c y f r o m t h e
system channels, high
system gains of up to
1 6 0 d B c a n b e
achieved without risking system lockup due to
the insufficient antenna isolation or high noise
floor problems that can be experienced with
BDA based solutions. In addition, it offers high
sensitivity and output power that makes the dis-
tribution system implementation very easy.
MOBEXCOM is compatible with major
trunking systems including SMARTNET™
and EDACS™
.
MOBEXCOM on the Move
Futurecom’s MOBEXCOM Vehicular Repeater
Systems are used by major police, ambulance
and fire agencies across North America. Their
robust construction and high specification make
them the only solution for these demanding
and lifesaving public safety applications.
WWide-area systems provide RF coverage
across cities, provinces, states or countries.
Reliable wide-area coverage has a number
of obvious benefits:
• For Private Mobile Radio network
operators it means higher system
loading, which translates into higher
air-time revenue.
• For public-safety radio systems such
as police, ambulance or fire, it means
improved safety, for both the public
and service personnel.
• For utility companies, it means
more efficient operations and
lower operating costs.
The obvious way to improve
wide-area coverage is
to expand the system
infrastructure. How-
ever, there are two
fundamental drawbacks to
this approach: high cost and
limited spectrum availability.
Futurecom Systems Group Inc. pro-
vides an economical and efficient way to
deal with difficult coverage situations.
Our MULTEXCOM site extenders, in VHF, UHF,
800 and 900 MHz frequency bands, pro-
vide a reliable and cost-effective RF coverage
extension for remote communities, highways
or hilly terrain.
Futurecom MULTEXCOM site extenders
allow backbone coverage to be increased
without spending millions of dollars on
expanding network infrastructures. MULTEX-
COM site extenders are fully transparent,
system and protocol independent, and can
be used in analog or digital systems for voice
or data.
SaskTel Selects MULTEXCOM 800
SaskTel Mobility, a division of SaskTel, a
crown corporation owned by the Province of
Saskatchewan, chose Futurecom
MULTEXCOM 800 to solve a
unique challenge of providing
instant and reliable radio com-
munications to a small population
spread across a vast
prairie province.
Simply expanding
t h e m a i n n e t w o r k
infrastructure would have
been prohibitively expensive,
requiring additional site equip-
ment, as well as the expansion of
multi-site switches and backhaul facilities.
SaskTel chose to base its FleetNet
8 0 0 o n E r i c s s o n ’s E D A C S®
t r u n k e d
system. Today FleetNet 800 is the largest
private radio network in the world, providing
radio coverage over 400,000 sq. km. Fleet-
N e t 8 0 0 o p e r a t e s w i t h m o r e t h a n
160 RF sites, almost half of which are
Futurecom MULTEXCOM 800 sites.
Wide Area CoverageWide Area Coverage
MULTEXCOMMULTEXCOM
SITEXCOM – Frequency Translating Repeater SITEXCOM Technical Highlights
Any site can be used as a donor. As shown in the diagram, the SITEXCOM receives downlink frequency F2 from the donor
site and translates it to frequency F4. Terminals receive frequency F4 and respond on F3. The SITEXCOM receives uplink
frequency F3 and translates it to F1. As a result the donor site sees its terminals operating on F1/F2. The SITEXCOM site
is transparent to both the donor and the network. Terminals see the SITEXCOM site as just another base station which they
can freely roam to. Thanks to its high sensitivity and high output power the SITEXCOM can dramatically increase the
donor’s coverage area.
SITEXCOM Applications
Boosting revenue and cutting costs is a universal recipe for improving profitability. In the case of wireless
network operators, boosting revenue comes from increasing the number of subscribers and enlarging the access area.
Cutting costs means doing it inexpensively. Multiplying the number of base stations may be prohibitively expensive and
ineffective in many low density areas.
Frequency Translating Repeater (SITEXCOM) is the network operator’s dream-come-true. It extends RF
coverage at a much lower cost than base stations and is ideal for large, low congestion areas, coverage gaps (valleys,
cliffs etc.), highways, buildings, and underground.
SITEXCOM
COVERAGE
GAPS
SITEXCOM
WIDE AREA
COVERAGE
SITEXCOM
IN BUILDING
COVERAGE
T1 T1 T1
SITEXCOM
HIGHWAY
COVERAGE
DONOR
DONOR
DONORDONOR
LOCAL SWITCH
DONOR
DONOR
Highly modular construction
Easy “rear door”
installation and access
Stainless steel
padlockable latches
Channel Selective
• Extends only desired channels.
• Does not create simulcast effects.
• Does not extend
competition’s channels.
• Does not create or propagate
intermod products.
High Sensitivity/High Power
• Provides good coverage.
Protocol Transparent
• All the donor’s present and future
site features are available in the
extended coverage area.
Wireless Interface
• Does not require any network
expansion or telephone line
connections.
Frequency Translating
• Does not create simulcast effects
on the donor’s channel.
• Can realize high system gain
(up to 163 dB).
On Channel (option)
• Uses the same channel as
a donor site.
• Ideal for applications where
simulcast is not a problem (e.g.
in buildings, underground etc.).
Factory Calibrated.
• Easy “no equipment” setup
• Only a laptop is needed
to setup a site.
Software Controlled
• Easy to reconfigure in the field.
Energy Efficient
• No fans needed.
• Efficient battery backup.
• Low hydro bills.
Highly Modular
• Easy to service and maintain.
Wireless Modem
Interface (option)
• Full remote alarm reporting.
• Full remote programming.
• Full remote monitoring.
Double Door Cabinet
• Easy two stage installation.
Small Size,
Weatherized Enclosure
• Pole or roof installable.
• Low site acquisition cost.
F1
F2
F1
F2
F3
F4
F3
F4
RF coverage by design
1-800-701-9180
broad-band amplifiers vehicular repeaters channel-selectiverepeaters
technology
18. VeracityCapitalInc.
Factors Favouring an Investment
in the Partnership
Strong Performance
• Year-to date (as of October 15, 2003), the Partnership has gained
17.7% net of all fees and expenses. On a trailing twelve-month basis,
the Partnership has gained approximately 16.8% net of all fees and
expenses. These gains were achieved with considerably lower volatility
than the overall equity markets.
Experienced Management
• Both Murray McDonald and Gregory Misztela, Managing Directors
of the General Partner, have considerable senior level experience in
managing alternative strategy equity pools and in investment research,
as well as over 30 years of combined experience in the financial
services industry. Mr.McDonald has managed hedge funds for
approximately ten years and generated average annual returns
in excess of 16%.
3
work samplesPavel Petrycki
artzone@sympatico.ca 416.949.4626 cell
Scotia Plaza • 40 King St. W., Suite 4900 • Toronto, ON M5H 4A2 416.777.6749 • 416.777.6784 Fax
Veracity Capital Inc.
K. Murray McDonald
Managing Director
murrmcd@attcanada.ca
Scotia Plaza
40 King St. W., Suite 4900
Toronto, ON M5H 4A2
416.777.6749
416.777.6784 Fax
Veracity Capital Inc.
Veracity Capital Inc.
Scotia Plaza • 40 King St. W., Suite 4900 • Toronto, ON M5H 4A2
VeracityCapitalInc.
Key Terms of the Offeringcont’d
Performance Fee
The General Partner is entitled to an annual performance fee equal to
20% of any increase in the net asset value of the units during each
calendar year.
Distribution of Income
Distributions may be made at the discretion of the General Partner.
Fiscal Year End
December 31 each year
Redemptions
Commencing June 30, 2003, provided the Limited Partner has held his
or her units for at least one year, units may be redeemed once a year
on thirty (30) days’ prior written notice. Limited partners may request
redemption at other times, but acceptance of such request is in the
discretion of the General Partner.
8
Veracity Capital Partners
Limited Partnership
(An Ontario Limited Partnership)
Minimum Subscription:
$150,000
($50,000 for
accredited investors)
416.864.6477
416.864.6485 Fax
1.866.269.7773 Toll Free
26 Wellington Street East, Suite 900
Toronto, ON M5E 1S2
www.mgisecurities.com
Joe Sample
VPMarketing & Research
416.864.6477x222
joesample@mgisecurities.com
26 Wellington Street East, Suite 900
Toronto, ON M5E 1S2
866.269.7773 Toll Free
416.864.6485 Fax
SECURITIES (USA) INC.
MEMBER OF THE JOVIAN GROUP OF COMPANIES
26 Wellington Street East, Suite 900
Toronto, ON M5E 1S2
Junior Oil & Gas Sector
Brian Kristjansen,Analyst
bkristjansen@mgisecurities.com 403-705-4969
Jeff Sears,CFA, Associate
jsears@mgisecurities.com403-705-4972
July 07, 2005
financial
